El-Shehaby Amr M N, Reda Wael A, Abdel Karim Khaled M, Nabeel Ahmed M, Emad Eldin Reem M, Alazzazi Ahmed H, Tawadros Sameh R
Gamma Knife Center Cairo, Nasser Institute Hospital, Cairo, Egypt.
Neurosurgery Department, Faculty of Medicine, Ain Shams University, Cairo, Egypt.
Sci Rep. 2025 May 25;15(1):18187. doi: 10.1038/s41598-025-03095-4.
Background and objectives Vestibular schwannomas are known to demonstrate tumor expansion, commonly referred to as pseudoprogression, after SRS. It is critical to differentiate between true tumor progression and pseudoprogression as this may entail performing an unnecessary intervention, such as surgery or repeat radiosurgery. This study aims to identify the fate of tumor enlargement that may occur after SRS for vestibular schwannomas and to propose a management algorithm for vestibular schwannoma enlargement after SRS. Methods In this retrospective study, we included 171 patients with sporadic vestibular schwannomas who showed tumor enlargement after SRS. The mean dose was 11.9 Gy (10-12 Gy). The mean tumor volume was 4.1 cc (0.1-19.7 cc). More than half of the tumors were Koos grade 4 (Koos 1: 8 (5%), 2: 20 (12%), 3: 43 (25%), 4: 100 (58%)). Volumetric changes and clinical outcomes were recorded. Different progression patterns were recorded according to the tumor volume changes (TVC) and the timings of TVC. Results The pseudoprogression rate among the patients who showed tumor enlargement after SRS was 83% (142/171). The mean follow-up duration was 64 months (12-241 months). The actuarial progression-free survival at 5-,7- and 10-years was 95%, 92%, and 90%, respectively. The mean follow-up duration was 64 months (12-241 months). The mean TVC at progression (TVCp) was 72% (11-439%). The mean time to tumor progression was 13 months (2-160 months) and the mean duration of TVC was 15 months (2-164 months). Late pseudoprogression (after 3 years) occurred in 30 patients (21%). In early PP, there was a shorter duration of volume change, and a presence of CLC. In true progression, there was a bigger TVCp, a bigger TVCf and a bigger tumor volume at the final follow-up (TVf). Clinical decline was observed with tumor enlargement in 36% of the patients, but in most of them, improvement occurred without the need for tumor intervention. Conclusion GKR for VS is associated with radiation-induced tumor enlargement in a group of patients. Pseudoprogression may occur beyond 5 years after treatment. A more conservative approach may be adopted in most vestibular schwannomas that exhibit tumor enlargement after SRS, as in most cases, they will eventually be controlled.
已知前庭神经鞘瘤在立体定向放射治疗(SRS)后会出现肿瘤扩大,通常称为假性进展。区分真正的肿瘤进展和假性进展至关重要,因为这可能需要进行不必要的干预,如手术或重复放射外科手术。本研究旨在确定前庭神经鞘瘤SRS后可能出现的肿瘤增大的转归,并提出SRS后前庭神经鞘瘤增大的处理算法。方法:在这项回顾性研究中,我们纳入了171例散发性前庭神经鞘瘤患者,这些患者在SRS后出现肿瘤增大。平均剂量为11.9 Gy(10 - 12 Gy)。平均肿瘤体积为4.1 cc(0.1 - 19.7 cc)。超过一半的肿瘤为库斯4级(库斯1级:8例(5%),2级:20例(12%),3级:43例(25%),4级:100例(58%))。记录体积变化和临床结果。根据肿瘤体积变化(TVC)和TVC的时间记录不同的进展模式。结果:SRS后出现肿瘤增大的患者中假性进展率为83%(142/171)。平均随访时间为64个月(12 - 241个月)。5年、7年和10年的无进展生存率分别为95%、92%和90%。平均随访时间为64个月(12 - 241个月)。进展时的平均TVC(TVCp)为72%(11 - 439%)。肿瘤进展的平均时间为13个月(2 - 160个月),TVC的平均持续时间为15个月(2 - 164个月)。30例患者(21%)出现晚期假性进展(3年后)。在早期假性进展中,体积变化持续时间较短,且存在CLC。在真正进展中,TVCp更大,TVCf更大,最后随访时肿瘤体积(TVf)更大。36%的患者在肿瘤增大时出现临床症状恶化,但大多数患者在无需肿瘤干预的情况下症状改善。结论:前庭神经鞘瘤的伽玛刀放射治疗(GKR)与一组患者中放射诱导的肿瘤增大有关。治疗后5年以上可能出现假性进展。对于大多数SRS后出现肿瘤增大的前庭神经鞘瘤,可采用更保守的方法,因为在大多数情况下,它们最终会得到控制。